Figure 3 | Scientific Reports

Figure 3

From: Maternal tadalafil therapy for fetal growth restriction prevents non-alcoholic fatty liver disease and adipocyte hypertrophy in the offspring

Figure 3

Histological examinations of tissues from the different treatment groups. (A) A liver at 20 weeks postnatally (HE stain, × 200 magnification). (B) Epididymal fatty cell area (HE stain, × 200 magnification). (C) F4/80 immunohistochemistry (arrow: positive cells, × 400 magnification). Morphologic changes in the liver and adipose tissue due to tadalafil and L-NAME administration. C + C indicates treatment naïve mice to whom no maternal intervention or HFD was given. Data are presented as the mean ± standard deviation, n = 4–7/group. ***p < 0.001, **p < 0.01, *p < 0.05, based on a one way-analysis of variance with a post hoc Tukey test for multiple comparisons. C + C control + control diet, C + H control + HFD, HE hematoxylin and eosin, HFD high-fat diet, L + H L-NG-nitroarginine methyl ester + high-fat diet, L-NAME L-NG-nitroarginine methyl ester, NAFLD non-alcoholic fatty liver disease, TL + H L-NAME + tadalafil + HFD, TL + H L-NG-nitroarginine methyl ester + tadalafil + high-fat diet.

Back to article page